| Citation: |
ZHANG Zhaoyuan, HE Shenghu, LIU Jia, ZHANG Jing. Analysis of CYP2C19 gene polymorphism detection in patients with coronary heart disease undergoing percutaneous coronary intervention in Yangzhou region[J]. Journal of Clinical Medicine in Practice, 2023, 27(23): 17-21. DOI: 10.7619/jcmp.20233246
|
To investigate the distribution differences of cytochrome P4502C19 (CYP2C19) gene polymorphisms and its impact on antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) in Yangzhou region.
A total of 215 patients diagnosed with coronary heart disease who underwent PCI from January 2021 to December 2022 in Yangzhou region were retrospectively selected as study objects. The age of the patients ranged from 37 to 93 years, with 152 males and 63 females. Polymerase chain reaction-sequencing was used to detect the CYP2C19 genotypes in the patients. The relationships of gender and age with distribution of CYP2C19 gene polymorphism were observed. Based on the metabolic types of CYP2C19 and the antiplatelet drugs used post-operatively, the patients were divided into fast-metabolizing clopidogrel group, medium-slow metabolizing clopidogrel group, fast-metabolizing ticagrelor group, medium-slow metabolizing ticagrelor group. After 6 months of follow-up, the incidence rates and severity of adverse events of cardiovascular ischemia and bleeding were compared among groups.
The CYP2C19 genotypes of 215 patients were distributed as follows: 81 cases of CYP2C19*1/*1 genotype, 93 cases of CYP2C19*1/*2, 10 cases of CYP2C19*1/*3, 25 cases of CYP2C19*2/*2, 6 cases of CYP2C19*2/*3. CYP2C19 metabolite types were fast metabolizers in 81 cases (37.67%), intermediate metabolizers in 103 cases (47.91%) and slow metabolizers in 31 cases (14.42%). The proportion of extensive metabolizers of CYP2C19 in the study patients was 37.67%, intermediate metabolizers accounted for 47.91%, and poor metabolizers accounted for 14.42%. There was no significant difference in the distribution of CYP2C19 genotype between different genders(χ2=0.346, P=0.987). There was no significant difference in the distribution of metabolic type between different genders (χ2=0.342, P=0.843). There was no significant difference in the distribution frequency of metabolic type among different age groups (χ2=1.098, P=0.895). The incidence of cardiovascular ischemia of adverse events in the fast-metabolizing clopidogrel group and the fast-metabolizing ticagrelor group was 16.67% and 14.29%, respectively, no significant difference was observed (P>0.05). The incidence of cardiovascular ischemia of adverse events in the medium-slow metabolized clopidogrel group was higher than that in the medium-slow metabolized ticagrelor group, and the difference was statistically significant (P < 0.05). There was no significant between-group difference in the incidence of bleeding of adverse events among groups(P>0.05).
In patients undergoing PCI for coronary heart disease in Yangzhou region, there is a polymorphism in the CYP2C19 gene with no significant differences between genders and age groups. The intermediate and fast metabolizers are more prevalent. It is clinically significant to perform CYP2C19 gene testing and adopt precise antiplatelet therapy for such patients.
| [1] |
韩宗茂, 高洁, 高传玉, 等. 经皮冠状动脉介入术中植入生物可吸收支架对冠心病患者远期预后的影响[J]. 中华实用诊断与治疗杂志, 2021, 35(1): 19-22. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZD202101005.htm
|
| [2] |
CASTRICHINI M, LUZUM J A, PEREIRA N. Pharmacogenetics of antiplatelet therapy[J]. Annu Rev Pharmacol Toxicol, 2023, 63: 211-229. doi: 10.1146/annurev-pharmtox-051921-092701
|
| [3] |
张艳双, 才艺, 赵晓杰, 等. 冠心病患者CYP2C19基因快代谢型与氯吡格雷抵抗作用研究[J]. 临床军医杂志, 2021, 49(10): 1144-1146. https://www.cnki.com.cn/Article/CJFDTOTAL-JYGZ202110022.htm
|
| [4] |
LEE C R, LUZUM J A, SANGKUHL K, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update[J]. Clin Pharmacol Ther, 2022, 112(5): 959-967. doi: 10.1002/cpt.2526
|
| [5] |
中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2022概要[J]. 中国循环杂志, 2023, 38(6): 583-612. https://www.cnki.com.cn/Article/CJFDTOTAL-XIXG202304001.htm
|
| [6] |
曾强, 解晔, 王劲松. 江苏省扬州市2018年心脑血管疾病全人群流行现状研究[J]. 实用临床医药杂志, 2019, 23(24): 37-40. doi: 10.7619/jcmp.201924012
|
| [7] |
卢永艳, 杜翠娴, 李晓君, 等. 老年冠心病PCI术后感染与CYP2C19基因多态性的关系[J]. 中华医院感染学杂志, 2021, 31(10): 1547-1551. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY202110024.htm
|
| [8] |
袁兆春, 牛祥, 芦伟, 等. CYP2C19基因多态性与老年冠状动脉粥样硬化性心脏病患者氯吡格雷抵抗的关系分析[J]. 中国临床医生杂志, 2023, 51(6): 653-655. doi: 10.3969/j.issn.2095-8552.2023.06.008
|
| [9] |
郭元元, 王丽英, 张宇, 等. 冠心病患者CYP2C19基因多态性及临床不良事件发生与氯吡格雷抵抗的关系[J]. 检验医学与临床, 2021, 18(8): 1054-1058. doi: 10.3969/j.issn.1672-9455.2021.08.008
|
| [10] |
宦丽君, 王鹏云. 湖北地区老年汉族人群CYP2C19*2、*3位点基因型分析[J]. 国际检验医学杂志, 2021, 42(24): 3014-3017. doi: 10.3969/j.issn.1673-4130.2021.24.016
|
| [11] |
鲍英, 钱福初, 傅铁钢, 等. 湖州地区人群CYP2C19基因多态性研究[J]. 中国卫生检验杂志, 2022, 32(19): 2398-2401. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWJZ202219023.htm
|
| [12] |
黄演婷, 陈小明, 杨小蓉, 等. 广州地区1899例心脑血管疾病患者CYP2C19基因多态性分析[J]. 广东药科大学学报, 2023, 39(2): 121-124. https://www.cnki.com.cn/Article/CJFDTOTAL-GDYX202302015.htm
|
| [13] |
吴贻晨, 陈点, 王尧城, 等. 福州地区汉族人群CYP2C19基因多态性分析及方法学比较[J]. 检验医学与临床, 2022, 19(14): 1907-1911. https://www.cnki.com.cn/Article/CJFDTOTAL-JYYL202214009.htm
|
| [14] |
钟新珠, 许鲁宁. CYP2C19基因多态性对PCI术后患者抗栓治疗的影响[J]. 临床合理用药, 2023, 16(2): 8-12. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202302003.htm
|
| [15] |
李兴, 卢姿瑾, 王晓冬, 等. CYP2C19基因多态性联合血小板功能检测指导PCI术后患者抗血小板药物选择的效果观察[J]. 首都医科大学学报, 2020, 41(6): 960-964. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYD202006016.htm
|
| [16] |
刘苗苗, 王勃, 韩东建, 等. CYP2C19基因检测在冠心病患者PCI后抗血小板药物治疗中的指导价值[J]. 实用心脑肺血管病杂志, 2023, 31(4): 14-19. https://www.cnki.com.cn/Article/CJFDTOTAL-SYXL202304003.htm
|
| [17] |
吴丹, 杨胜利, 路靖, 等. 冠心病患者支架术后根据检测药物代谢酶CYP2C19基因调整抗血小板治疗的价值[J]. 中国循环杂志, 2015, 30(3): 216-219. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXH201503005.htm
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: